Cargando…

Nanocarriers-Mediated Drug Delivery Systems for Anticancer Agents: An Overview and Perspectives

Nanotechnology has been actively integrated as drug carriers over the last few years to treat various cancers. The main hurdle in the clinical management of cancer is the development of multidrug resistance against chemotherapeutic agents. To overcome the limitations of chemotherapy, the researchers...

Descripción completa

Detalles Bibliográficos
Autores principales: Edis, Zehra, Wang, Junli, Waqas, Muhammad Khurram, Ijaz, Muhammad, Ijaz, Munazza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7898224/
https://www.ncbi.nlm.nih.gov/pubmed/33628022
http://dx.doi.org/10.2147/IJN.S289443
_version_ 1783653821299294208
author Edis, Zehra
Wang, Junli
Waqas, Muhammad Khurram
Ijaz, Muhammad
Ijaz, Munazza
author_facet Edis, Zehra
Wang, Junli
Waqas, Muhammad Khurram
Ijaz, Muhammad
Ijaz, Munazza
author_sort Edis, Zehra
collection PubMed
description Nanotechnology has been actively integrated as drug carriers over the last few years to treat various cancers. The main hurdle in the clinical management of cancer is the development of multidrug resistance against chemotherapeutic agents. To overcome the limitations of chemotherapy, the researchers have been developing technological advances for significant progress in the oncotherapy by enabling the delivery of chemotherapeutic agents at increased drug content levels to the targeted spots. Several nano-drug delivery systems designed for tumor-targeting are evaluated in preclinical and clinical trials and showed promising outcomes in cancerous tumors’ clinical management. This review describes nanocarrier’s importance in managing different types of cancers and emphasizing nanocarriers for drug delivery and cancer nanotherapeutics. It also highlights the recent advances in nanocarriers-based delivery systems, including polymeric nanocarriers, micelles, nanotubes, dendrimers, magnetic nanoparticles, solid lipid nanoparticles, and quantum dots (QDs). The nanocarrier-based composites are discussed in terms of their structure, characteristics, and therapeutic applications in oncology. To conclude, the challenges and future exploration opportunities of nanocarriers in chemotherapeutics are also presented.
format Online
Article
Text
id pubmed-7898224
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-78982242021-02-23 Nanocarriers-Mediated Drug Delivery Systems for Anticancer Agents: An Overview and Perspectives Edis, Zehra Wang, Junli Waqas, Muhammad Khurram Ijaz, Muhammad Ijaz, Munazza Int J Nanomedicine Review Nanotechnology has been actively integrated as drug carriers over the last few years to treat various cancers. The main hurdle in the clinical management of cancer is the development of multidrug resistance against chemotherapeutic agents. To overcome the limitations of chemotherapy, the researchers have been developing technological advances for significant progress in the oncotherapy by enabling the delivery of chemotherapeutic agents at increased drug content levels to the targeted spots. Several nano-drug delivery systems designed for tumor-targeting are evaluated in preclinical and clinical trials and showed promising outcomes in cancerous tumors’ clinical management. This review describes nanocarrier’s importance in managing different types of cancers and emphasizing nanocarriers for drug delivery and cancer nanotherapeutics. It also highlights the recent advances in nanocarriers-based delivery systems, including polymeric nanocarriers, micelles, nanotubes, dendrimers, magnetic nanoparticles, solid lipid nanoparticles, and quantum dots (QDs). The nanocarrier-based composites are discussed in terms of their structure, characteristics, and therapeutic applications in oncology. To conclude, the challenges and future exploration opportunities of nanocarriers in chemotherapeutics are also presented. Dove 2021-02-17 /pmc/articles/PMC7898224/ /pubmed/33628022 http://dx.doi.org/10.2147/IJN.S289443 Text en © 2021 Edis et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Edis, Zehra
Wang, Junli
Waqas, Muhammad Khurram
Ijaz, Muhammad
Ijaz, Munazza
Nanocarriers-Mediated Drug Delivery Systems for Anticancer Agents: An Overview and Perspectives
title Nanocarriers-Mediated Drug Delivery Systems for Anticancer Agents: An Overview and Perspectives
title_full Nanocarriers-Mediated Drug Delivery Systems for Anticancer Agents: An Overview and Perspectives
title_fullStr Nanocarriers-Mediated Drug Delivery Systems for Anticancer Agents: An Overview and Perspectives
title_full_unstemmed Nanocarriers-Mediated Drug Delivery Systems for Anticancer Agents: An Overview and Perspectives
title_short Nanocarriers-Mediated Drug Delivery Systems for Anticancer Agents: An Overview and Perspectives
title_sort nanocarriers-mediated drug delivery systems for anticancer agents: an overview and perspectives
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7898224/
https://www.ncbi.nlm.nih.gov/pubmed/33628022
http://dx.doi.org/10.2147/IJN.S289443
work_keys_str_mv AT ediszehra nanocarriersmediateddrugdeliverysystemsforanticanceragentsanoverviewandperspectives
AT wangjunli nanocarriersmediateddrugdeliverysystemsforanticanceragentsanoverviewandperspectives
AT waqasmuhammadkhurram nanocarriersmediateddrugdeliverysystemsforanticanceragentsanoverviewandperspectives
AT ijazmuhammad nanocarriersmediateddrugdeliverysystemsforanticanceragentsanoverviewandperspectives
AT ijazmunazza nanocarriersmediateddrugdeliverysystemsforanticanceragentsanoverviewandperspectives